Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.
Identifieur interne : 001119 ( PubMed/Corpus ); précédent : 001118; suivant : 001120Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.
Auteurs : E. Van Den Neste ; N. Schmitz ; N. Mounier ; D. Gill ; D. Linch ; M. Trneny ; R. Bouadballah ; J. Radford ; M. Bargetzi ; V. Ribrag ; U. Dührsen ; D. Ma ; J. Briere ; C. Thieblemont ; E. Bachy ; C H Moskowitz ; B. Glass ; C. GisselbrechtSource :
- Bone marrow transplantation [ 1476-5365 ] ; 2017.
Abstract
In the CORAL study, 255 chemosensitive relapses with diffuse large B-cell lymphoma (DLBCL) were consolidated with autologous stem cell transplantation (ASCT), and 75 of them relapsed thereafter. The median time between ASCT and progression was 7.1 months. The median age was 56.1 years; tertiary International Prognosis Index (tIPI) observed at relapse was 0-2 in 71.6% of the patients and >2 in 28.4%. The overall response rate to third-line chemotherapy was 44%. The median overall survival (OS) was 10.0 months (median follow-up: 32.8 months). Thirteen patients received an allogeneic SCT, and three a second ASCT. The median OS was shorter among patients who relapsed <6 months (5.7 months) compared with those relapsing ⩾12 months after ASCT (12.6 months, P=0.0221). The median OS in patients achieving CR, PR or no response after the third-line regimen was 37.7 (P<0.0001), 10.0 (P=0.03) and 6.3 months, respectively. The median OS varied according to tIPI: 0-2: 12.6 months and >2: 5.3 months (P=0.0007). In multivariate analysis, tIPI >2, achievement of response and remission lasting <6 months predicted the OS. This report identifies the prognostic factors for DLBCL relapsing after ASCT and thus helps to select patients for experimental therapy.
DOI: 10.1038/bmt.2016.213
PubMed: 27643872
Links to Exploration step
pubmed:27643872Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.</title><author><name sortKey="Van Den Neste, E" sort="Van Den Neste, E" uniqKey="Van Den Neste E" first="E" last="Van Den Neste">E. Van Den Neste</name><affiliation><nlm:affiliation>Cliniques Universitaires UCL Saint-Luc, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Schmitz, N" sort="Schmitz, N" uniqKey="Schmitz N" first="N" last="Schmitz">N. Schmitz</name><affiliation><nlm:affiliation>AsklepiosKlinik St Georg, AbteilungHämatologie und Stammzelltransplantation, Hamburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Mounier, N" sort="Mounier, N" uniqKey="Mounier N" first="N" last="Mounier">N. Mounier</name><affiliation><nlm:affiliation>CHU de l'Archet, route de St Antoine-Ginestiere, Nice, France.</nlm:affiliation></affiliation></author><author><name sortKey="Gill, D" sort="Gill, D" uniqKey="Gill D" first="D" last="Gill">D. Gill</name><affiliation><nlm:affiliation>Princess Alexandra Hospital, Woodville, South Australia, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Linch, D" sort="Linch, D" uniqKey="Linch D" first="D" last="Linch">D. Linch</name><affiliation><nlm:affiliation>University College London, Cancer Institute, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Trneny, M" sort="Trneny, M" uniqKey="Trneny M" first="M" last="Trneny">M. Trneny</name><affiliation><nlm:affiliation>Charles University and General Hospital, Praha, Czech Republic.</nlm:affiliation></affiliation></author><author><name sortKey="Bouadballah, R" sort="Bouadballah, R" uniqKey="Bouadballah R" first="R" last="Bouadballah">R. Bouadballah</name><affiliation><nlm:affiliation>Institut Paoli Calmette Département d'Onco-Hématologie, Institut Paoli-Calmettes, Marseille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Radford, J" sort="Radford, J" uniqKey="Radford J" first="J" last="Radford">J. Radford</name><affiliation><nlm:affiliation>University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Bargetzi, M" sort="Bargetzi, M" uniqKey="Bargetzi M" first="M" last="Bargetzi">M. Bargetzi</name><affiliation><nlm:affiliation>Hämatologie, Kantonsspital Aarau, Aarau, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Ribrag, V" sort="Ribrag, V" uniqKey="Ribrag V" first="V" last="Ribrag">V. Ribrag</name><affiliation><nlm:affiliation>Institut Gustave Roussy, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Duhrsen, U" sort="Duhrsen, U" uniqKey="Duhrsen U" first="U" last="Dührsen">U. Dührsen</name><affiliation><nlm:affiliation>Universitätsklinikum Essen, KlinikfürHämatologie-Hufelandstraße, Essen, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Ma, D" sort="Ma, D" uniqKey="Ma D" first="D" last="Ma">D. Ma</name><affiliation><nlm:affiliation>St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Briere, J" sort="Briere, J" uniqKey="Briere J" first="J" last="Briere">J. Briere</name><affiliation><nlm:affiliation>Hopital Saint Louis Paris, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Thieblemont, C" sort="Thieblemont, C" uniqKey="Thieblemont C" first="C" last="Thieblemont">C. Thieblemont</name><affiliation><nlm:affiliation>Hopital Saint Louis Paris, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Bachy, E" sort="Bachy, E" uniqKey="Bachy E" first="E" last="Bachy">E. Bachy</name><affiliation><nlm:affiliation>Hospices Civils de Lyon, Université de Lyon, Pierre Benite, France.</nlm:affiliation></affiliation></author><author><name sortKey="Moskowitz, C H" sort="Moskowitz, C H" uniqKey="Moskowitz C" first="C H" last="Moskowitz">C H Moskowitz</name><affiliation><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Glass, B" sort="Glass, B" uniqKey="Glass B" first="B" last="Glass">B. Glass</name><affiliation><nlm:affiliation>AsklepiosKlinik St Georg, AbteilungHämatologie und Stammzelltransplantation, Hamburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Gisselbrecht, C" sort="Gisselbrecht, C" uniqKey="Gisselbrecht C" first="C" last="Gisselbrecht">C. Gisselbrecht</name><affiliation><nlm:affiliation>Hopital Saint Louis Paris, Paris, France.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:27643872</idno><idno type="pmid">27643872</idno><idno type="doi">10.1038/bmt.2016.213</idno><idno type="wicri:Area/PubMed/Corpus">001119</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001119</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.</title><author><name sortKey="Van Den Neste, E" sort="Van Den Neste, E" uniqKey="Van Den Neste E" first="E" last="Van Den Neste">E. Van Den Neste</name><affiliation><nlm:affiliation>Cliniques Universitaires UCL Saint-Luc, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Schmitz, N" sort="Schmitz, N" uniqKey="Schmitz N" first="N" last="Schmitz">N. Schmitz</name><affiliation><nlm:affiliation>AsklepiosKlinik St Georg, AbteilungHämatologie und Stammzelltransplantation, Hamburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Mounier, N" sort="Mounier, N" uniqKey="Mounier N" first="N" last="Mounier">N. Mounier</name><affiliation><nlm:affiliation>CHU de l'Archet, route de St Antoine-Ginestiere, Nice, France.</nlm:affiliation></affiliation></author><author><name sortKey="Gill, D" sort="Gill, D" uniqKey="Gill D" first="D" last="Gill">D. Gill</name><affiliation><nlm:affiliation>Princess Alexandra Hospital, Woodville, South Australia, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Linch, D" sort="Linch, D" uniqKey="Linch D" first="D" last="Linch">D. Linch</name><affiliation><nlm:affiliation>University College London, Cancer Institute, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Trneny, M" sort="Trneny, M" uniqKey="Trneny M" first="M" last="Trneny">M. Trneny</name><affiliation><nlm:affiliation>Charles University and General Hospital, Praha, Czech Republic.</nlm:affiliation></affiliation></author><author><name sortKey="Bouadballah, R" sort="Bouadballah, R" uniqKey="Bouadballah R" first="R" last="Bouadballah">R. Bouadballah</name><affiliation><nlm:affiliation>Institut Paoli Calmette Département d'Onco-Hématologie, Institut Paoli-Calmettes, Marseille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Radford, J" sort="Radford, J" uniqKey="Radford J" first="J" last="Radford">J. Radford</name><affiliation><nlm:affiliation>University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Bargetzi, M" sort="Bargetzi, M" uniqKey="Bargetzi M" first="M" last="Bargetzi">M. Bargetzi</name><affiliation><nlm:affiliation>Hämatologie, Kantonsspital Aarau, Aarau, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Ribrag, V" sort="Ribrag, V" uniqKey="Ribrag V" first="V" last="Ribrag">V. Ribrag</name><affiliation><nlm:affiliation>Institut Gustave Roussy, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Duhrsen, U" sort="Duhrsen, U" uniqKey="Duhrsen U" first="U" last="Dührsen">U. Dührsen</name><affiliation><nlm:affiliation>Universitätsklinikum Essen, KlinikfürHämatologie-Hufelandstraße, Essen, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Ma, D" sort="Ma, D" uniqKey="Ma D" first="D" last="Ma">D. Ma</name><affiliation><nlm:affiliation>St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Briere, J" sort="Briere, J" uniqKey="Briere J" first="J" last="Briere">J. Briere</name><affiliation><nlm:affiliation>Hopital Saint Louis Paris, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Thieblemont, C" sort="Thieblemont, C" uniqKey="Thieblemont C" first="C" last="Thieblemont">C. Thieblemont</name><affiliation><nlm:affiliation>Hopital Saint Louis Paris, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Bachy, E" sort="Bachy, E" uniqKey="Bachy E" first="E" last="Bachy">E. Bachy</name><affiliation><nlm:affiliation>Hospices Civils de Lyon, Université de Lyon, Pierre Benite, France.</nlm:affiliation></affiliation></author><author><name sortKey="Moskowitz, C H" sort="Moskowitz, C H" uniqKey="Moskowitz C" first="C H" last="Moskowitz">C H Moskowitz</name><affiliation><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Glass, B" sort="Glass, B" uniqKey="Glass B" first="B" last="Glass">B. Glass</name><affiliation><nlm:affiliation>AsklepiosKlinik St Georg, AbteilungHämatologie und Stammzelltransplantation, Hamburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Gisselbrecht, C" sort="Gisselbrecht, C" uniqKey="Gisselbrecht C" first="C" last="Gisselbrecht">C. Gisselbrecht</name><affiliation><nlm:affiliation>Hopital Saint Louis Paris, Paris, France.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Bone marrow transplantation</title><idno type="eISSN">1476-5365</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the CORAL study, 255 chemosensitive relapses with diffuse large B-cell lymphoma (DLBCL) were consolidated with autologous stem cell transplantation (ASCT), and 75 of them relapsed thereafter. The median time between ASCT and progression was 7.1 months. The median age was 56.1 years; tertiary International Prognosis Index (tIPI) observed at relapse was 0-2 in 71.6% of the patients and >2 in 28.4%. The overall response rate to third-line chemotherapy was 44%. The median overall survival (OS) was 10.0 months (median follow-up: 32.8 months). Thirteen patients received an allogeneic SCT, and three a second ASCT. The median OS was shorter among patients who relapsed <6 months (5.7 months) compared with those relapsing ⩾12 months after ASCT (12.6 months, P=0.0221). The median OS in patients achieving CR, PR or no response after the third-line regimen was 37.7 (P<0.0001), 10.0 (P=0.03) and 6.3 months, respectively. The median OS varied according to tIPI: 0-2: 12.6 months and >2: 5.3 months (P=0.0007). In multivariate analysis, tIPI >2, achievement of response and remission lasting <6 months predicted the OS. This report identifies the prognostic factors for DLBCL relapsing after ASCT and thus helps to select patients for experimental therapy.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">27643872</PMID><DateCreated><Year>2016</Year><Month>09</Month><Day>19</Day></DateCreated><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5365</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Bone marrow transplantation</Title><ISOAbbreviation>Bone Marrow Transplant.</ISOAbbreviation></Journal><ArticleTitle>Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.</ArticleTitle><Pagination><MedlinePgn>216-221</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/bmt.2016.213</ELocationID><Abstract><AbstractText>In the CORAL study, 255 chemosensitive relapses with diffuse large B-cell lymphoma (DLBCL) were consolidated with autologous stem cell transplantation (ASCT), and 75 of them relapsed thereafter. The median time between ASCT and progression was 7.1 months. The median age was 56.1 years; tertiary International Prognosis Index (tIPI) observed at relapse was 0-2 in 71.6% of the patients and >2 in 28.4%. The overall response rate to third-line chemotherapy was 44%. The median overall survival (OS) was 10.0 months (median follow-up: 32.8 months). Thirteen patients received an allogeneic SCT, and three a second ASCT. The median OS was shorter among patients who relapsed <6 months (5.7 months) compared with those relapsing ⩾12 months after ASCT (12.6 months, P=0.0221). The median OS in patients achieving CR, PR or no response after the third-line regimen was 37.7 (P<0.0001), 10.0 (P=0.03) and 6.3 months, respectively. The median OS varied according to tIPI: 0-2: 12.6 months and >2: 5.3 months (P=0.0007). In multivariate analysis, tIPI >2, achievement of response and remission lasting <6 months predicted the OS. This report identifies the prognostic factors for DLBCL relapsing after ASCT and thus helps to select patients for experimental therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Van Den Neste</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Cliniques Universitaires UCL Saint-Luc, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmitz</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>AsklepiosKlinik St Georg, AbteilungHämatologie und Stammzelltransplantation, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mounier</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>CHU de l'Archet, route de St Antoine-Ginestiere, Nice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Princess Alexandra Hospital, Woodville, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linch</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University College London, Cancer Institute, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trneny</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Charles University and General Hospital, Praha, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouadballah</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institut Paoli Calmette Département d'Onco-Hématologie, Institut Paoli-Calmettes, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radford</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bargetzi</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hämatologie, Kantonsspital Aarau, Aarau, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ribrag</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institut Gustave Roussy, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dührsen</LastName><ForeName>U</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Universitätsklinikum Essen, KlinikfürHämatologie-Hufelandstraße, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Briere</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hopital Saint Louis Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thieblemont</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hopital Saint Louis Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bachy</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hospices Civils de Lyon, Université de Lyon, Pierre Benite, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moskowitz</LastName><ForeName>C H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>AsklepiosKlinik St Georg, AbteilungHämatologie und Stammzelltransplantation, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gisselbrecht</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hopital Saint Louis Paris, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Bone Marrow Transplant</MedlineTA><NlmUniqueID>8702459</NlmUniqueID><ISSNLinking>0268-3369</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 1999 Apr;17(4):1244</RefSource><PMID Version="1">10561185</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2004 Jan 1;103(1):275-82</RefSource><PMID Version="1">14504078</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2010 Sep 20;28(27):4184-90</RefSource><PMID Version="1">20660832</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2008 Nov;19(11):1935-40</RefSource><PMID Version="1">18684698</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biol Blood Marrow Transplant. 2010 Jan;16(1):78-85</RefSource><PMID Version="1">19744569</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2012 Nov 15;120(20):4256-62</RefSource><PMID Version="1">23007405</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Haematol. 2016 Jul;174(2):235-48</RefSource><PMID Version="1">26989808</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Hematol. 2014 Aug;93(8):1345-51</RefSource><PMID Version="1">24633661</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2011 Apr 1;29(10):1342-8</RefSource><PMID Version="1">21321299</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2014 Jun;15(7):757-66</RefSource><PMID Version="1">24827808</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bone Marrow Transplant. 2015 Oct;50(10):1286-92</RefSource><PMID Version="1">26146806</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2012 Dec 20;30(36):4462-9</RefSource><PMID Version="1">23091101</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 1992 Oct 15;80(8):2142-8</RefSource><PMID Version="1">1356515</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bone Marrow Transplant. 2016 Jan;51(1):51-7</RefSource><PMID Version="1">26367239</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Cancer. 2015 Dec 11;14:207</RefSource><PMID Version="1">26654227</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bone Marrow Transplant. 2016 Mar;51(3):365-71</RefSource><PMID Version="1">26618550</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2011 Nov 1;29(31):4079-87</RefSource><PMID Version="1">21947824</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bone Marrow Transplant. 2014 May;49(5):671-8</RefSource><PMID Version="1">24510071</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am Soc Clin Oncol Educ Book. 2015;:e449-57</RefSource><PMID Version="1">25993209</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Hematol. 2012 Jun;91(6):931-9</RefSource><PMID Version="1">22245922</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Haematol. 2014 Mar;164(5):668-74</RefSource><PMID Version="1">24274082</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Expert Rev Anticancer Ther. 2015 Apr;15(4):439-51</RefSource><PMID Version="1">25652253</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Hematol. 2013 Oct;88(10):890-4</RefSource><PMID Version="1">23813874</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>04</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>06</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>07</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27643872</ArticleId><ArticleId IdType="pii">bmt2016213</ArticleId><ArticleId IdType="doi">10.1038/bmt.2016.213</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001119 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001119 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27643872
|texte= Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27643872" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |